The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

@article{Grimwade1998TheIO,
  title={The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.},
  author={David Grimwade and Helen Walker and Fiona Oliver and Keith Wheatley and Christine J Harrison and Georgina Harrison and J. K. H. Rees and Ian M. Hann and Richard L. Stevens and Alan K Burnett and A. H. Goldstone},
  journal={Blood},
  year={1998},
  volume={92 7},
  pages={
          2322-33
        }
}
Cytogenetics is considered one of the most valuable prognostic determinants in acute myeloid leukemia (AML). However, many studies on which this assertion is based were limited by relatively small sample sizes or varying treatment approach, leading to conflicting data regarding the prognostic implications of specific cytogenetic abnormalities. The Medical Research Council (MRC) AML 10 trial, which included children and adults up to 55 years of age, not only affords the opportunity to determine… 
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.
TLDR
St stratification demonstrated that a large subgroup of patients, characterized by age 70 or older or high-risk cytogenetics, or both, had very unfavorable treatment results despite intensive chemotherapy, demonstrating that karyotype and age are major determinants of outcome in elderly patients with AML.
The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG)
TLDR
The results support the importance of cytogenetic analysis in childhood AML, but show that further work is required in the classification of the poor prognosis aberrations.
Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse
TLDR
The results indicate that both karyotype and the duration of first CR are independent prognostic factors for patients with de novo, chemotherapy-treated AML in first relapse.
Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.
  • K. Klein, G. Kaspers, +27 authors B. Gibson
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015
TLDR
Pediatric patients with t(8;21)-AML and additional del(9q) or additional +4 might not be considered at good risk, but likely benefit from protocols that have high doses of anthracyclines, etoposide, and cytarabine during induction, as well as from protocols comprising cumulative high doses.
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
TLDR
This study suggests that hierarchical cytogenetic classification identifies biologically distinct subsets of AML that are represented in all age groups, and highlights the importance of karyotype as a critical independent determinant of outcome in older patients with AML.
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
TLDR
Although the prognostic impact of many recurring abnormalities has not been ascertained independently of complex karyotype, cytogenetics is among the most useful factors predicting attainment of CR, CIR, and long-term survival in adult AML.
Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution
TLDR
It was showed that outcome after allo-SCT in de novo AML differs depending on cytogenetic risk-group; however its position in post-remission therapy of eligible AML patients is not threatened.
Management of patients with cytogenetically normal acute myeloid leukemia who have neither favorable nor unfavorable markers.
TLDR
Treatment outcomes for this group of patients after chemotherapy and autologous and allogeneic stem cell transplantation are reviewed and new recurrent somatic mutations and their prognostic significance in patients with FLT3 wild-type/NPM1 wild- type CN-AML are addressed.
Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.
  • Y. Chalandon, M. Barnett, +8 authors D. Hogge
  • Medicine
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2002
TLDR
It is suggested that presentation karyotype has less prognostic significance for outcome following allo-BMT than for outcomes following conventional chemotherapy.
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.
TLDR
Analysis of outcomes of 5876 patients treated in Medical Research Council trials allows more reliable prediction of outcome for patients with rarer abnormalities and may facilitate the development of consensus in reporting of karyotypic information in clinical trials involving younger adults with AML.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 47 REFERENCES
Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases
TLDR
The findings do not support the previously reported ‘favourable’ prognosis of t(15;17) translocations, but suggest that the prognosis associated with t(9;11) or its variants (at least in adults), and trisomy 8 might be less severe than suggested in other studies.
Establishing the presence of the t( 15; 17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial
TLDR
Although PML immunofluorescence staining is suitable for rapid determination of patients likely to benefit from ATRA, this approach does not obviate the need for cytogenetic and RT-PCR analysis of all patients entered into APL clinical trials, because both techniques provide additional information which may prove to be of independent prognostic significance.
The clinical significance of karyotype in acute myelogenous leukemia.
Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission.
TLDR
It is concluded that cytogenetic abnormalities correlated with increased relapse in patients treated with chemotherapy, and HLA-identical sibling transplants are similar.
Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study.
  • J. Slack, D. Arthur, +10 authors C. Bloomfield
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1997
TLDR
Primary cytogenetic changes do not confer a poor prognosis in APL patients treated with anthracycline/cytarabine (Ara-C)-based chemotherapy and a highly significant relationship exists between the PML-RAR alpha 5 isoform (intron 3 PML genomic breakpoint) and secondary cytogenetics changes inAPL.
Karyotype in acute myeloblastic leukemia: prognostic significance in a prospective study assessing bone marrow transplantation in first remission.
TLDR
It is shown that the karyotype retains its prognostic value when the intentions is to treat patients with acute myeloblastic leukemia in CR1 with BMT.
Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome.
TLDR
An analysis was conducted of clinical and laboratory variables associated with response to remission induction therapy and remission duration in 440 patients with acute myelogenous leukemia, finding specific cytogenetic abnormalities such as t(8;21), t(15;17), and inv16 were found to be favorable for response to therapy and/or remission duration.
Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML.
TLDR
The expected correlations of rather immature myeloid immunologic phenotypes with M1 and M2 morphology and CD14 expression in monoblastic leukemias was found and remission rate and survival were significantly worse in 19 patients with complex nonrandom aberrations, where blast cell expression of blood group H antigen and of TdT were significantly increased.
Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group.
TLDR
A group of 201 adult patients with de novo acute myeloid leukemia were investigated to determine the prognostic significance of karyotype on early death, drug resistance, continuous complete remission (CCR) and survival probabilities at 5 years.
...
1
2
3
4
5
...